Drug Information

Drug General Information
Drug ID
D0NY1R
Former ID
DIB000392
Drug Name
AC-3174
Synonyms
GLP-1 agonist (type 2 diabetes), Amylin Pharmaceuticals; Glucagon-like peptide-1 receptor agonist (type 2diabetes/non-alcoholic steatohepatitis), Amylin Pharmaceuticals; (Leu14)exendin-4
Drug Type
Small molecular drug
Indication Non-alcoholic steatohepatitis [ICD9: 571.8; ICD10:K76.0] Investigative [530376], [532841], [551186]
Company
Amylin Pharmaceuticals Inc
Structure
Download
2D MOL

3D MOL
Formula
C5H3BrClN
Canonical SMILES
N1(C(=O)[C@H]2N(C(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[<br />C@@H](NC(=O)[C@H]3N(C(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@<br />@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]<br />(NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(<br />=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)<br />[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@<br />@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]<br />(NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc<br />4nc[nH]c4)N)CCC(=O)O)[C@H](O)C)Cc4ccccc4)[C@H](O)C)CO)C<br />C(=O)O)CC(C)C)CO)CCCCN)CCC(=O)N)CC(C)C)CCC(=O)O)CCC(=O)<br />O)CCC(=O)O)C)C(C)C)CCCNC(=N)N)CC(C)C)Cc4ccccc4)[C@H](CC<br />)C)CCC(=O)O)Cc4c[nH]c5c4cccc5)CC(C)C)CCCCN)CC(=O)N)CCC3<br />)CO)CO)C)CCC2)[C@H](C(=O)N2[C@H](C(=O)N[C@H](C(=O)N)CO)<br />CCC2)CCC1
PubChem Compound ID
817098
Target and Pathway
Target(s) Glucagon-like peptide 1 receptor Target Info Agonist [530376], [532841], [551186]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Insulin secretion
Reactome Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
G alpha (s) signalling events
Glucagon-type ligand receptors
WikiPathways GPCRs, Class B Secretin-like
Integration of energy metabolism
GPCR ligand binding
GPCR downstream signaling
References
Ref 530376Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77.
Ref 532841Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR). Rev Med Liege. 2014 Apr;69(4):214-9.
Ref 5511862005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
Ref 530376Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77.
Ref 532841Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR). Rev Med Liege. 2014 Apr;69(4):214-9.
Ref 5511862005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.